The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Treatment of Toxic Epidermal Necrolysis With High-Dose Intravenous Immunoglobulins: Multicenter Retrospective Analysis of 48 Consecutive Cases
Open accessAbstract
OBJECTIVE: To evaluate the effect of high-dose intravenous immunoglobulin (IVIG) in toxic epidermal necrolysis (TEN), parameters that may affect response to treatment, and the effect of different IVIG batches on Fas-mediated cell death. DESIGN: Multicenter retrospective analysis of 48 consecutive TEN patients treated with IVIG. SETTING: Fourteen university hospital dermatology centers in Europe and the United States. PATIENTS: Forty-eight patients with TEN (skin detachment >10% of their body surface [mean, 44.8%; range, 10%-95%]). INTERVENTIONS: Infusion of IVIG in all patients (range, 0.8-5.8 g/kg), and analysis of the ability of different IVIG batches to inhibit Fas-mediated cell death. MAIN OUTCOME MEASURES: Objective response to IVIG treatment, final outcome at day 45, parameters that may affect response to IVIG treatment, and tolerance. RESULTS: Infusion of IVIG (mean total dose, 2.7 g/kg [range, 0.65-5.8 g/kg]; mean consecutive days, 4 [range, 1-5 days]) was associated with a rapid cessation (mean, 2.3 days [range, 1-6 days]) of skin and mucosal detachment in 43 patients (90%) and survival in 42 (88%). Patients who responded to IVIG had received treatment earlier in the course of disease and, on average, higher doses of IVIG. Furthermore, analysis of 35 IVIG batches revealed significant batch-to-batch variations in the capacity of IVIG to inhibit Fas-mediated cell death in vitro. CONCLUSIONS: Early infusion of high-dose IVIG is safe, well tolerated, and likely to be effective in improving the survival of patients with TEN. We recommend early treatment with IVIG at a total dose of 3 g/kg over 3 consecutive days (1 g/kg per day for 3 days).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bastuji‐Garin, S. (1993) · Archives of Dermatology · doi:10.1001/archderm.129.1.92 · Cited by 1,697
Severe Adverse Cutaneous Reactions to Drugs
Roujeau, J. C., & Stern, R. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311906 · Cited by 1,571
Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin
Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J.-H., Tschopp, J., & French, L. E. (1998) · Science · doi:10.1126/science.282.5388.490 · Cited by 1,005
Self-citationInhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
(1999) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(99)80071-6 · Cited by 869
Manipulating the Immune System with Immune Globulin
Oates, J. A., Wood, A. J. J., & Dwyer, J. M. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201093260206 · Cited by 648
The estimation of areas of burns
Cc, L. (1944) · Medical Entomology and Zoology · Cited by 560
Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
Wolkenstein, P., Latarjet, J., Roujeau, J.-C., Duguet, C., Boudeau, S., Vaillant, L., Maignan, M., Schuhmacher, M.-H., Milpied, B., Pilorget, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02197-7 · Cited by 428
Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome: An Epidemiologic Study From West Germany
Schöpf, E. (1991) · Archives of Dermatology · doi:10.1001/archderm.1991.01680050083008 · Cited by 399
Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients
Revuz, J. E. (1987) · Archives of Dermatology · doi:10.1001/archderm.123.9.1160 · Cited by 395
Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985
Roujeau, J. (1990) · Archives of Dermatology · doi:10.1001/archderm.126.1.37 · Cited by 391
Cited by
Drug Allergy: An Updated Practice Parameter
(2010) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2010.08.002 · Cited by 957
Toxic epidermal necrolysis and Stevens-Johnson syndrome
Harr, T., & French, L. E. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-39 · Cited by 693
Self-citationPrevention of toxic epidermal necrolysis by regulatory T cells
Azukizawa, H., Sano, S., Kosaka, H., Sumikawa, Y., & Itami, S. (2005) · European Journal of Immunology · doi:10.1002/eji.200425773 · Cited by 380
Pereira, F. A., Mudgil, A. V., & Rosmarin, D. M. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.04.048 · Cited by 376
Clinical uses of intravenous immunoglobulin
Jolles, S., Sewell, W. A. C., & Misbah, S. A. (2005) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2005.02834.x · Cited by 374
Metadata
- Authors
- Prins, C., Kerdel, F. A., Padilla, R. S., Hunziker, T., Chimenti, S., Viard, I., Mauri, D. N., Flynn, K., Trent, J., Margolis, D. J., Saurat, J.-H., French, L. E., & for the TEN-IVIG Study Group
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2003-01-01
- Volume
- 139
- Issue
- 1
- Pages
- 26
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W2121050460
- Cited by
- 325
- References
- 20
- FWCI
- 18.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Toxic Epidermal Necrolysis With High-Dose Intravenous Immunoglobulins: Multicenter Retrospective Analysis of 48 Consecutive Cases. https://app.cochat.ai/papers/10.1001/archderm.139.1.26
- The paper
- Prins, C., Kerdel, F. A., Padilla, R. S., Hunziker, T., Chimenti, S., Viard, I., Mauri, D. N., Flynn, K., Trent, J., Margolis, D. J., Saurat, J.-H., French, L. E., & for the TEN-IVIG Study Group. (2003). Treatment of Toxic Epidermal Necrolysis With High-Dose Intravenous Immunoglobulins: Multicenter Retrospective Analysis of 48 Consecutive Cases. Archives of Dermatology. https://doi.org/10.1001/archderm.139.1.26
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.